Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016:2016:9675171.
doi: 10.1155/2016/9675171. Epub 2016 Nov 8.

Myeloproliferative Disease: An Unusual Cause of Raynaud's Phenomenon and Digital Ischaemia

Affiliations

Myeloproliferative Disease: An Unusual Cause of Raynaud's Phenomenon and Digital Ischaemia

Celia Beynon et al. Case Rep Med. 2016.

Abstract

We describe a 59-year-old female who presented with ischaemic digits, preceded by a 6-month history of Raynaud's phenomenon affecting her fingers and toes. There were no clinical or laboratory features of primary vasculitis or connective tissue disease, Doppler imaging was normal, and bloods were unremarkable aside from a platelet count of 786 × 109/L (150-400) and white cells of 16 × 109/L (4-11). In view of the thrombocytosis a JAK2 mutation assay was requested which confirmed a JAK2 V617F mutation, suggesting essential thrombocytosis (ET) as the cause. She received treatment with hydroxycarbamide which normalised her platelet count and led to a complete resolution of her Raynaud's symptoms. Raynaud's phenomenon is a rare manifestation of ET. Myeloproliferative disorders such as ET should be considered in the differential diagnosis of Raynaud's phenomenon and vasculitis.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests to declare.

Figures

Figure 1
Figure 1
Left foot of a 59-year-old patient presenting to rheumatology clinic.

References

    1. Rozman C., Giralt M., Feliu E., Rubio D., Cortes M.-T. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer. 1991;67(10):2658–2663. doi: 10.1002/1097-0142(19910515)67:10<2658::aid-cncr2820671042>3.0.co;2-c. - DOI - PubMed
    1. Mesa R. A., Silverstein M. N., Jacobsen S. J., Wollan P. C., Tefferi A. Population based incidence and survival figures in essential thrombocythaemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976–1995. American Journal of Hematology. 1976;61(1):10–15. - PubMed
    1. Takata Y., Seki R., Kanajii T., et al. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms. The Kurume medical journal. 2014;60(3-4):89–97. doi: 10.2739/kurumemedj.MS63001. - DOI - PubMed
    1. Carobbio A., Finazzi G., Antonioli E., et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood. 2008;112(8):3135–3137. doi: 10.1182/blood-2008-04-153783. - DOI - PMC - PubMed
    1. Itin P. H., Winkelmann R. K. Cutaneous manifestations in patients with essential thrombocythemia. Journal of the American Academy of Dermatology. 1991;24(1):59–63. doi: 10.1016/0190-9622(91)70010-y. - DOI - PubMed

LinkOut - more resources